This Biotech CEO Is Using Neuroplastogenic Small-Molecule Therapeutics To Create Next Generation Mental Health. Dr Joseph Tucker – CEO Enveric $ENVB

This Biotech CEO Is Using Neuroplastogenic Small-Molecule
Therapeutics To Create Next Generation Mental Health. Dr Joseph
Tucker – CEO Enveric $ENVB








Guest:


Dr. Joseph Tucker – CEO – Enveric Biosciences





Website:


https://www.enveric.com/





Company Bio:


Enveric Biosciences, Inc., a biotechnology company, engages in
the development of small-molecule therapeutics for the treatment
of anxiety, depression, and addiction disorders. Its lead product
candidates are EB-002, an active metabolite of psilocybin, which
is in preclinical development stage for the treatment of anxiety
disorders; and EB-003 that is in preclinical development stage
for the treatment mental health. The company also focuses on the
development of cannabinoid conjugate molecules for the treatment
of pain and cancer. Enveric Biosciences, Inc. is headquartered in
Naples, Florida.





Dr. Tucker Bio:


Dr. Tucker is a seasoned executive who has built several publicly
traded biotechnology companies. Dr. Tucker was a founder and
Chief Executive Officer of Stem Cell Therapeutics, which he took
public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ:
TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr.
Tucker has also held the position of Co-Founder and Chief
Executive Officer of Epimeron Inc., a University of Calgary
start-up acquired in the creation of Willow Biosciences Inc.
(TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman
and Chief Operating Officer. Prior to founding companies, Dr.
Tucker was a healthcare analyst with two investment banks and has
also worked in technology commercialization for a university
technology transfer office. Dr. Tucker received his Ph.D. in
Biochemistry and Molecular Biology from the University of
Calgary.